Mangoceuticals (MGRX) Competitors $2.25 +0.03 (+1.35%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$2.17 -0.08 (-3.56%) As of 09/19/2025 06:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MGRX vs. ATPC, PIII, BDSX, EUDA, BMGL, CCM, MRAI, BRTX, BGLC, and SSYShould you be buying Mangoceuticals stock or one of its competitors? The main competitors of Mangoceuticals include Agape ATP (ATPC), P3 Health Partners (PIII), Biodesix (BDSX), EUDA Health (EUDA), Basel Medical Group (BMGL), Concord Medical Services (CCM), Marpai (MRAI), Biorestorative Therapies (BRTX), BioNexus Gene Lab (BGLC), and SunLink Health Systems (SSY). These companies are all part of the "healthcare" industry. Mangoceuticals vs. Its Competitors Agape ATP P3 Health Partners Biodesix EUDA Health Basel Medical Group Concord Medical Services Marpai Biorestorative Therapies BioNexus Gene Lab SunLink Health Systems Agape ATP (NASDAQ:ATPC) and Mangoceuticals (NASDAQ:MGRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment. Is ATPC or MGRX more profitable? Agape ATP has a net margin of -183.13% compared to Mangoceuticals' net margin of -2,757.86%. Agape ATP's return on equity of -20.32% beat Mangoceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Agape ATP-183.13% -20.32% -18.55% Mangoceuticals -2,757.86%-85.01%-78.08% Do insiders & institutionals have more ownership in ATPC or MGRX? 0.0% of Agape ATP shares are held by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are held by institutional investors. 9.7% of Agape ATP shares are held by insiders. Comparatively, 16.0% of Mangoceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media favor ATPC or MGRX? In the previous week, Agape ATP had 1 more articles in the media than Mangoceuticals. MarketBeat recorded 1 mentions for Agape ATP and 0 mentions for Mangoceuticals. Agape ATP's average media sentiment score of 0.95 beat Mangoceuticals' score of 0.00 indicating that Agape ATP is being referred to more favorably in the media. Company Overall Sentiment Agape ATP Positive Mangoceuticals Neutral Which has more volatility & risk, ATPC or MGRX? Agape ATP has a beta of -0.98, meaning that its share price is 198% less volatile than the S&P 500. Comparatively, Mangoceuticals has a beta of 2.45, meaning that its share price is 145% more volatile than the S&P 500. Which has higher valuation & earnings, ATPC or MGRX? Agape ATP has higher revenue and earnings than Mangoceuticals. Agape ATP is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAgape ATP$1.32M48.87-$2.47M-$0.41-3.15Mangoceuticals$620K38.25-$8.71M-$3.86-0.58 SummaryAgape ATP beats Mangoceuticals on 9 of the 13 factors compared between the two stocks. Get Mangoceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MGRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MGRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGRX vs. The Competition Export to ExcelMetricMangoceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.39M$2.58B$5.80B$10.40BDividend YieldN/A55.37%5.63%4.60%P/E Ratio-0.5823.0276.8226.78Price / Sales38.25689.96532.95124.28Price / CashN/A175.2537.9961.55Price / Book0.525.3513.746.40Net Income-$8.71M$32.95M$3.30B$271.80M7 Day Performance-0.88%0.90%2.65%3.48%1 Month Performance48.51%5.76%6.04%9.89%1 Year Performance-96.00%-3.43%80.14%28.51% Mangoceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGRXMangoceuticals0.7728 of 5 stars$2.25+1.4%N/A-96.1%$23.39M$620K-0.583Gap DownATPCAgape ATP0.7247 of 5 stars$1.30+1.2%N/A-32.8%$64.01M$1.32M-3.1640PIIIP3 Health Partners2.7297 of 5 stars$8.38-2.9%$16.25+93.9%-63.0%$62M$1.50B-0.18500BDSXBiodesix3.6923 of 5 stars$6.56-13.7%$35.00+433.5%-80.0%$55.72M$71.32M-1.13220News CoveragePositive NewsAnalyst ForecastStock SplitEUDAEUDA Health0.1807 of 5 stars$1.10+3.8%N/A-66.8%$39.39M$4.01M0.002Gap DownBMGLBasel Medical GroupN/A$2.07+4.5%N/AN/A$36.54MN/A0.0036Positive NewsCCMConcord Medical Services1.2767 of 5 stars$5.65-1.1%N/A+8.9%$24.79M$52.60M0.00970Short Interest ↓Gap UpMRAIMarpaiN/A$1.11-8.3%N/A+63.2%$19.17M$34.87M-0.42150News CoverageGap UpHigh Trading VolumeBRTXBiorestorative Therapies1.181 of 5 stars$1.48-2.0%N/A-12.7%$12.05M$400K-1.177Gap UpBGLCBioNexus Gene Lab0.1507 of 5 stars$5.22+4.0%N/A+29.4%$9.02M$9.51M0.0030SSYSunLink Health SystemsN/A$1.12+16.6%N/A+42.1%$7.88M$31.09M4.661,376Gap Up Related Companies and Tools Related Companies ATPC Alternatives PIII Alternatives BDSX Alternatives EUDA Alternatives BMGL Alternatives CCM Alternatives MRAI Alternatives BRTX Alternatives BGLC Alternatives SSY Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGRX) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mangoceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mangoceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MGRX Stock Alerts